The chemicals industry is one of the world’s largest industrial sectors, worth €3,471 billion in 2020. It includes producers of industrial chemicals, polymers, pesticides, food and feed additives, and cosmetics, and is growing rapidly. By some estimates it will reach almost $22,000 billion by 2060.
Traditional batch chemistry is too inefficient for a sustainable future. Switching batch processing to continuous processing is inevitable if the world is to reach net zero.
For decades, Ferrate(VI) has been known as the strongest oxidant in the world for the treatment of (industrial) wastewater.
Interview with Marc Doyle, CEO of Arxada, which was created following the carve-out and sale of Lonza Specialty Ingredients to private equity firms Bain Capital and Cinven.
Interview with Karl Rotthier, CEO of the Sanofi spin-off EuroAPI.
Executives and industry experts share their views on drivers as well as barriers for the use of flow chemistry in pharmaceutical manufacturing and the prospect for this technology in their industry sector.
Executives and industry experts share their views on drivers as well as barriers for the use of flow chemistry in pharmaceutical manufacturing and the prospect for this technology in their industry sector.
Executives and industry experts share their views on drivers as well as barriers for the use of flow chemistry in pharmaceutical manufacturing and the prospect for this technology in their industry sector.
Executives and industry experts share their views on drivers as well as barriers for the use of flow chemistry in pharmaceutical manufacturing and the prospect for this technology in their industry sector.
Executives and industry experts share their views on drivers as well as barriers for the use of flow chemistry in pharmaceutical manufacturing and the prospect for this technology in their industry sector.
Executives and industry experts share their views on drivers as well as barriers for the use of flow chemistry in pharmaceutical manufacturing and the prospect for this technology in their industry sector.
Executives and industry experts share their views on drivers as well as barriers for the use of flow chemistry in pharmaceutical manufacturing and the prospect for this technology in their industry sector.
Executives and industry experts share their views on drivers as well as barriers for the use of flow chemistry in pharmaceutical manufacturing and the prospect for this technology in their industry sector.
Executives and industry experts share their views on drivers as well as barriers for the use of flow chemistry in pharmaceutical manufacturing and the prospect for this technology in their industry sector.
The Serbian Elixir Group has made a name for itself as one of the leading producers of mineral fertilizers and phosphoric acid in Eastern Europe.
Japan continues to be one of the largest pharmaceutical markets in the world, making up approximately 7% of the global share. Historically, Japan has been viewed as insular compared to other developed markets such as Europe or the US, with foreign companies reporting high barriers to entry.
The primary goal for any manufacturing or process organization is to produce a profit and return on net asset (RONA) to shareholders and other stakeholders. Safety and environmental performance are secondary goals – not secondary in importance, but no manufacturing plant was ever built with the sole and explicit purpose of being safe and environmentally responsible.
With 1,650 employees and an annual turnover of EUR 320 million, the Serbian Elixir Group is one of the leading mineral fertilizer and phosphoric acid producers in Eastern Europe.
There is a new urgency in the market for manufacturers and testing organizations to be prepared for rapid, unexpected changes in material resource access, exacerbated by turbulent regional and global events. This focus is in addition to reinforcing routine risk mitigation activities around the raw material supply chain, adding to the relevance and impact of the topic.
Interview with Joachim Haupt and Florian Kaiser, PharmAI
The value in applying AI in Pharma is in making new and better drugs available faster than would be possible otherwise. By augmenting sparse-data AI with expert knowledge and applying it to the latest nanoparticle engineering techniques, opportunities are created to eliminate the risk associated with new techniques and give therapeutics a second chance to reach the patients who need them.
Management pays a lot of attention to new ideas and cutting-edge technologies, but most of their resources are consumed by mature legacy technologies that are often not actively and rigorously managed. A visual matrix can help teams understand which technologies offer the greatest long-term potential for businesses.
For many years, fine and specialty chemicals markets were on a robust growth path.
In many industrial applications the wet sulfuric acid process is the most important technology for recovery of sulfuric acid and energy from sulfur bearing compounds.
At an online roundtable event hosted by CHEManager, a group of industry experts discussed the reasons why microreaction technology (MRT) has not achieved the status for instance in fine chemicals and active ingredients production that one might expect as well as various business and production aspects of the technology.
The global market for oligonucleotide therapeutics is expanding rapidly. Bachem, an innovation-driven company based in Bubendorf, Switzerland, has entered this competitive environment a few years ago and meanwhile has passed certain milestones on its way to become a preferred oligonucleotide manufacturing partner for pharmaceutical companies.
Storage conditions play a vital role in the entire supply chain of pharmaceutical products and must comply with strict regulations. From manufacturers to patients, storage conditions are essential for the quality, safety, and efficacy of medications.
The positive impacts of Predictive Maintenance are broad and should be considered holistically. No one ever said that nurturing a perfect rose garden was simple, but the results can be dramatic.
Interview with Oliver Reimann and Andreas Regnery, Belyntic
Biovox was founded in 2020 to enable more sustainability through renewable bioplastics even in difficult applications such as consumables in healthcare or machine parts.
Munio is developing streamlined and efficient learning and access systems that enable business park operators to offer flexibility to their tenants while maintaining control.
